Levosimendan in Acute and Advanced Heart Failure: an Expert Perspective on Posology and Therapeutic Application
Clicks: 61
ID: 271813
2018
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
18.0
/100
61 views
33 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #19 of 22 articles by views in cardiovascular drugs and therapy
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Levosimendan, a calcium sensitizer and potassium channel-opener, is widely appreciated by many specialist heart failure practitioners for its effects on systemic and pulmonary hemodynamics and for the relief of symptoms of acute heart failure. The drug’s ...
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (37 words).
Try re-searching for a better abstract.
| Reference Key |
tschöpe2018cardiovascularlevosimendan
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | S. Bouchez, F. Fedele, G. Giannakoulas, F. Gustafsson, V.-P. Harjola, K. Karason, M. Kivikko, D. von Lewinski, F. Oliva, Z. Papp, J. Parissis, Piero Pollesello, G. Pölzl, C. Tschöpe;S. Bouchez;F. Fedele;G. Giannakoulas;F. Gustafsson;V.-P. Harjola;K. Karason;M. Kivikko;D. von Lewinski;F. Oliva;Z. Papp;J. Parissis;Piero Pollesello;G. Pölzl;C. Tschöpe; |
| Journal | cardiovascular drugs and therapy |
| Year | 2018 |
| DOI |
10.1007/s10557-018-6838-2
|
| URL | |
| Keywords |
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.